SRPT:NGS-Sarepta Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 149.25

Change

-1.00 (-0.67)%

Market Cap

USD 1.99B

Volume

1.12M

Analyst Target

USD 193.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-6.88 (-1.37%)

USD 126.85B
REGN Regeneron Pharmaceuticals Inc

+1.39 (+0.13%)

USD 117.19B
MRNA Moderna Inc

+0.38 (+0.32%)

USD 46.95B
ARGX argenx NV ADR

+6.66 (+1.31%)

USD 30.45B
ALNY Alnylam Pharmaceuticals Inc

+3.65 (+1.56%)

USD 29.58B
BGNE BeiGene Ltd

+9.60 (+6.12%)

USD 16.93B
RPRX Royalty Pharma Plc

-0.37 (-1.30%)

USD 16.81B
BMRN Biomarin Pharmaceutical Inc

-0.06 (-0.07%)

USD 15.97B
UTHR United Therapeutics Corporatio..

-24.25 (-7.18%)

USD 14.60B
INCY Incyte Corporation

-2.72 (-4.01%)

USD 12.98B

ETFs Containing SRPT

PINK Simplify Exchange Traded .. 12.57 % 0.00 %

-0.01 (0.82%)

USD 0.18B
MSGR 6.12 % 0.00 %

N/A

N/A
XDNA:CA 5.41 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.11 % 0.00 %

+0.18 (+0.82%)

N/A
GN0M:XETRA Global X Genomics & Biote.. 4.86 % 0.00 %

+0.04 (+0.82%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.86 % 0.00 %

-0.07 (0.82%)

USD 5.83M
CURG:LSE VanEck Genomics and Healt.. 4.67 % 0.00 %

+0.13 (+0.82%)

USD 7.04M
GNOG:LSE Global X Genomics & Biote.. 4.07 % 0.00 %

+0.05 (+0.82%)

USD 6.19M
CURE:AU ETFS S&P Biotech ETF 3.32 % 0.00 %

+0.16 (+0.82%)

USD 0.04B
ETLI:XETRA L&G Pharma Breakthrough U.. 3.00 % 0.00 %

+0.07 (+0.82%)

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 3.00 % 0.00 %

+0.04 (+0.82%)

N/A
BTEC Principal Healthcare Inno.. 2.71 % 0.42 %

+0.40 (+0.82%)

USD 0.02B
HEAL:SW iShares Healthcare Innova.. 1.99 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 1.98 % 0.00 %

+0.09 (+0.82%)

USD 2.77M
W311:XETRA HAN-GINS Indxx Healthcare.. 1.87 % 0.00 %

+0.03 (+0.82%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.87 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.87 % 0.00 %

+0.03 (+0.82%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.87 % 0.00 %

N/A

N/A
2B78:F iShares Healthcare Innova.. 1.75 % 0.00 %

+0.10 (+0.82%)

N/A
WDNA 1.74 % 0.00 %

N/A

N/A
WDNA:LSE WisdomTree BioRevolution .. 1.73 % 0.00 %

+0.17 (+0.82%)

N/A
2B78:XETRA iShares Healthcare Innova.. 1.70 % 0.00 %

+0.07 (+0.82%)

USD 1.14B
LABU Direxion Daily S&P Biotec.. 1.66 % 1.14 %

+0.69 (+0.82%)

USD 1.11B
THNZ:XETRA L&G Global Thematic ESG E.. 0.80 % 0.00 %

+0.13 (+0.82%)

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.77 % 0.00 %

+0.16 (+0.82%)

N/A
AGED:SW iShares Ageing Population.. 0.68 % 0.00 %

+0.05 (+0.82%)

N/A
2B77:F iShares Ageing Population.. 0.61 % 0.00 %

+0.06 (+0.82%)

N/A
CSY8:F Credit Suisse Index Fund .. 0.60 % 0.00 %

+1.54 (+0.82%)

USD 0.55B
CSY8:XETRA Credit Suisse Index Fund .. 0.60 % 0.00 %

+1.56 (+0.82%)

USD 0.55B
USSMC:SW Credit Suisse Index Fund .. 0.60 % 0.00 %

+1.88 (+0.82%)

N/A
2B77:XETRA iShares Ageing Population.. 0.59 % 0.00 %

+0.03 (+0.82%)

USD 0.50B
QBTL:CA AGFiQ US Market Neutral A.. 0.45 % 0.00 %

-0.19 (0.82%)

CAD 0.26B
H41G:XETRA HSBC MSCI World Small Cap.. 0.39 % 0.00 %

+0.26 (+0.82%)

N/A
VISM:AU Vanguard MSCI Internation.. 0.18 % 0.00 %

+1.25 (+0.82%)

USD 0.29B
ZPRS:F SSgA SPDR ETFs Europe II .. 0.17 % 0.00 %

+1.59 (+0.82%)

USD 0.83B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.17 % 0.00 %

+1.12 (+0.82%)

USD 0.83B
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 0.00 %

-0.27 (0.82%)

N/A
LABS 0.00 % 0.45 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

+0.06 (+0.82%)

USD 0.09B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

+0.06 (+0.82%)

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+3.25 (+0.82%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

+8.45 (+0.82%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.07 (+0.82%)

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+5.25 (+0.82%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.08 (+0.82%)

N/A
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

+0.07 (+0.82%)

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

+0.09 (+0.82%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.05 (+0.82%)

N/A
PAMC Pacer Lunt MidCap Multi-F.. 0.00 % 0.00 %

+0.08 (+0.82%)

USD 0.06B
DWEQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 54.78% 87% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.78% 87% B+ 92% A
Trailing 12 Months  
Capital Gain 38.21% 82% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.21% 82% B 87% B+
Trailing 5 Years  
Capital Gain -4.39% 71% C- 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.39% 71% C- 46% F
Average Annual (5 Year Horizon)  
Capital Gain 9.35% 67% D+ 67% D+
Dividend Return 9.35% 67% D+ 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.83% 58% F 35% F
Risk Adjusted Return 19.55% 76% C+ 55% F
Market Capitalization 1.99B 98% N/A 95% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 376.28 5% 4%
Price/Book Ratio 13.43 11% 8%
Price / Cash Flow Ratio -30.53 96% 91%
Price/Free Cash Flow Ratio -24.82 95% 91%
Management Effectiveness  
Return on Equity 2.02% 96% 62%
Return on Invested Capital -14.09% 82% 37%
Return on Assets -1.89% 95% 49%
Debt to Equity Ratio 131.79% 14% 17%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.